Connie Marcus

713 total citations
8 papers, 570 citations indexed

About

Connie Marcus is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Connie Marcus has authored 8 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Cancer Research and 1 paper in Molecular Biology. Recurrent topics in Connie Marcus's work include Breast Cancer Treatment Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Global Cancer Incidence and Screening (2 papers). Connie Marcus is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Global Cancer Incidence and Screening (2 papers). Connie Marcus collaborates with scholars based in United States and United Kingdom. Connie Marcus's co-authors include Aman U. Buzdar, Terry L. Smith, George R. Blumenschein, Frankie A. Holmes, Gabriel N. Hortobágyi, Verena Hug, G. N. Hortobágyi, Hwee‐Yong Yap, E. A. Gehan and Thomas J. Kean and has published in prestigious journals such as Cancer, Oncology and American Journal of Clinical Oncology.

In The Last Decade

Connie Marcus

8 papers receiving 546 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Connie Marcus United States 7 288 153 150 140 95 8 570
Elena Strocchi Italy 18 350 1.2× 87 0.6× 53 0.4× 203 1.4× 177 1.9× 52 771
Luíz Henrique Gebrim Brazil 15 251 0.9× 202 1.3× 206 1.4× 22 0.2× 147 1.5× 92 735
Gabriella Camboni Italy 17 341 1.2× 45 0.3× 45 0.3× 73 0.5× 349 3.7× 26 821
Frank Lawton United Kingdom 14 112 0.4× 51 0.3× 165 1.1× 32 0.2× 187 2.0× 39 858
P. Schein United States 10 196 0.7× 26 0.2× 39 0.3× 114 0.8× 144 1.5× 18 578
Thomas Budd United States 12 176 0.6× 42 0.3× 109 0.7× 67 0.5× 127 1.3× 21 591
Keith Moser Austria 10 133 0.5× 39 0.3× 53 0.4× 55 0.4× 121 1.3× 80 358
Pilar Zamora Spain 17 303 1.1× 50 0.3× 202 1.3× 21 0.1× 270 2.8× 55 795
Beverly Word United States 17 139 0.5× 60 0.4× 89 0.6× 25 0.2× 348 3.7× 35 693
Domenico Giordano Italy 16 282 1.0× 37 0.2× 19 0.1× 31 0.2× 164 1.7× 50 1.0k

Countries citing papers authored by Connie Marcus

Since Specialization
Citations

This map shows the geographic impact of Connie Marcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Connie Marcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Connie Marcus more than expected).

Fields of papers citing papers by Connie Marcus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Connie Marcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Connie Marcus. The network helps show where Connie Marcus may publish in the future.

Co-authorship network of co-authors of Connie Marcus

This figure shows the co-authorship network connecting the top 25 collaborators of Connie Marcus. A scholar is included among the top collaborators of Connie Marcus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Connie Marcus. Connie Marcus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Buzdar, Aman U., Connie Marcus, Frankie A. Holmes, Verena Hug, & Gabriel N. Hortobágyi. (1988). Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer. Oncology. 45(5). 344–345. 134 indexed citations
2.
Buzdar, Aman U., Gabriel N. Hortobágyi, Terry L. Smith, et al.. (1988). Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 62(10). 2098–2104. 22 indexed citations
3.
Buzdar, Aman U., et al.. (1986). Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute.. PubMed. 81–5. 16 indexed citations
4.
Hortobágyi, G. N., Aman U. Buzdar, Connie Marcus, & Terry L. Smith. (1986). Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.. PubMed. 105–9. 93 indexed citations
5.
Buzdar, Aman U., Connie Marcus, George R. Blumenschein, & Terry L. Smith. (1985). Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 55(12). 2761–2765. 251 indexed citations
6.
Buzdar, A., Terry L. Smith, Connie Marcus, G. N. Hortobagyi, & George R. Blumenschein. (1984). Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer. Recent results in cancer research. 96. 141–147. 3 indexed citations
7.
Buzdar, Aman U., Hwee‐Yong Yap, George R. Blumenschein, et al.. (1984). Combined modality approach in breast cancer with isolated or multiple metastases. American Journal of Clinical Oncology. 7(1). 45–50. 24 indexed citations
8.
Kean, Thomas J., et al.. (1981). The breast self-examination practices of high risk women: Implications for patient education. PubMed. 3(3). 103–107. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026